Luseogliflozin Improves Glycemic Metrics and Metabolic Outcomes in T2DM Read more about Luseogliflozin Improves Glycemic Metrics and Metabolic Outcomes in T2DM
Insulin Therapy and Plasma Volume Status Impact In-Hospital Mortality in CHF-T2DM Read more about Insulin Therapy and Plasma Volume Status Impact In-Hospital Mortality in CHF-T2DM
Automated Insulin Delivery Significantly Improves One-Year Outcomes in T1DM Tags Others Delivery devices Read more about Automated Insulin Delivery Significantly Improves One-Year Outcomes in T1DM
Semaglutide Shows Potential Anti-Inflammatory Benefit in T2DM Read more about Semaglutide Shows Potential Anti-Inflammatory Benefit in T2DM
Hormone Profiles Highlight Variation in Dulaglutide Response Read more about Hormone Profiles Highlight Variation in Dulaglutide Response
Basal Insulin Intensification After Tirzepatide Improves Glycemic Control in T2DM Read more about Basal Insulin Intensification After Tirzepatide Improves Glycemic Control in T2DM
Fixed-Dose Combination Therapy Enhances Glycemic and Renal Outcomes in T2DM With CKD Read more about Fixed-Dose Combination Therapy Enhances Glycemic and Renal Outcomes in T2DM With CKD
Tirzepatide Leads Once-Weekly GLP-1 Class in Glycemic and Weight Outcomes Read more about Tirzepatide Leads Once-Weekly GLP-1 Class in Glycemic and Weight Outcomes
GLP-1 Receptor Agonists Provide Consistent Cardiovascular and Renal Benefit Across Drug Class Read more about GLP-1 Receptor Agonists Provide Consistent Cardiovascular and Renal Benefit Across Drug Class
SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity